July 8, 2024
Since its founding in 2015, Imperative Care has maintained an unwavering commitment to elevating care for stroke and vascular patients. We take intellectual property rights seriously, and we are confident that we do not infringe on any valid U.S. patents. We have invested heavily in research and development for our products. Our technologies were developed with a clear understanding of the shortcomings of existing technologies, and with the sole objective of serving the needs of physicians and their patients. Today’s IPR filing is one of many steps we will take to defend our commitment to innovation vigorously.
The anticompetitive behavior of the incumbent aims to quell innovation that would ultimately improve patient care and outcomes. Anything that reduces the number of treatment options available compromises the wellbeing of patients with devastating vascular diseases. At Imperative Care, we put the needs of patients at the center of everything we do, and we remain focused on advancing life-saving technologies for patients.